2. GPCR/G Protein Neuronal Signaling NF-κB
  3. Orexin Receptor (OX Receptor) NF-κB
  4. BGB-A445

BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma[1][2].

For research use only. We do not sell to patients.

BGB-A445 Chemical Structure

BGB-A445 Chemical Structure

CAS No. : 3033874-57-3

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BGB-A445 Related Antibodies

Top Publications Citing Use of Products

View All Orexin Receptor (OX Receptor) Isoform Specific Products:

View All Isoforms
OX2 Receptor OX1 Receptor

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma[1][2].

IC50 & Target

TNFRSF4/OX40/CD134
In Vitro

BGB-A445 (0.01-10 µg/mL, 1 h) binds potently to cell-surface-overexpressed OX40 in a dose-dependent manner with an EC50 of 0.219 µg/mL in HuT78 cells and an EC50 of 0.157 µg/mL in primary human CD4+ T cells[1].

BGB-A445 (0-10 µg/mL, 48 h) induces DC (dendritic cell) maturation by upregulating the DC maturation/activation markers CD83 and CD86 levels[1].

BGB-A445 (0.0001-10 µg/mL, 48 h) dose-dependently enhances IL-2 production in HuT78/OX40 cells (EC50 = 0.059 µg/mL) and primary CD4+ T cells[1].

BGB-A445 (0.001-10 µg/mL, overnight) induces ADCC against tumor Tregs with high OX40 levels and high percentages of OX40-expressing cells[1].

BGB-A445 (0.001-10 µg/mL, overnight) increased the percentage of CD8+ cells while reducing the percentage of Tregs among T cells in PBMCs[1].

BGB-A445 (0.1-10 µg/mL, 48 h) significantly promoted IL-2 secretion by primary T cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BGB-A445 Related Antibodies
In Vivo

BGB-A445 (0.3-10 mg/kg, i.p. weekly for 2-4 times) exhibits potent anti-tumor activity and increases the proliferation of Teffs in a dose-dependent manner in MC38, CT26WT and PAN02 syngeneic mice models[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MC38 tumor mice model[1]
Dosage: 0.3, 1, 3 and 10 mg/kg
Administration: Intraperitoneal injection, weekly for 2 times
Result: Dose-dependently increased the number of CD4 Teffs, CD8 T cells and proliferating (Ki67+) Teffs, including CD4 T effector cells (CD3+CD4+FOXP3−) andCD8 T cells (CD3+CD8+).
Demonstrated significantly more potent activation in promoting the proliferation of CD8 T cells and memory phenotype CD8 T cells.
Dose-dependently increased the CD8+/Treg ratios.
Animal Model: MC38 syngeneic model[1]
Dosage: 0.4, 2, and 10 mg/kg
Administration: Intraperitoneal injection, weekly for 2 times
Result: Showed dose-dependent antitumor efficacy with the TGI rates of 14%, 80%, and 78%, respectively.
Animal Model: Anti-PD1-resistant PAN02 syngeneic model[1]
Dosage: 2 mg/kg
Administration: Intraperitoneal injection, once a week for about 32 days
Result: Achieved a TGI rate of 75% by day 32 and showed no reduction of body weight at 3 mg/kg.
Animal Model: CT26WT tumor model[2]
Dosage: 2 mg/kg
Administration: Intraperitoneal injection, once a week for about 28 days
Result: Suppressed the tumor growth.
Gene ID

7293  [NCBI]

Accession
Target

TNFRSF4/OX40/CD134
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
CAS No.
SMILES

N/A
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BGB-A445 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BGB-A4453033874-57-3Orexin Receptor (OX Receptor)NF-κBHypocretin ReceptorHCRT ReceptorNuclear factor-κBNuclear factor-kappaBOX40CD4+ T cellsADCCTregsMC38 modelPAN02 c modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BGB-A445
Cat. No.:
HY-P991613
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.